Entereg eases recovery from postoperative ileus
Entereg is cleared to restore bowel function to patients who have undergone abdominal surgery.
Tips to Remember Entereg
Alvimopan's product labeling includes a boxed warning stating that the drug is available only for short-term use (15 doses) and for hospitals that complete a registration process [Entereg Access Support and Education (E.A.S.E.) program] designed to prevent outpatient use of the drug. This Risk Evaluation and Mitigation Strategy (REMS) seeks to ensure that the benefits of the drug outweigh the risks. These precautions are likely a result of preliminary Phase III data indicating an increased incidence of neoplasms and cardiovascular events among patients treated with alvimopan over a 12-month period for chronic opioid-induced bowel dysfunction. In contrast, methylnaltrexone does not appear to have these safety issues but it is contraindicated in those with GI obstruction.
THE AUTHOR is a writer and hospital pharmacist based in New Jersey.
Pharmacists Play Unique Role in Advancing Health Equity for Patients With Chronic Disease
December 7th 2023A new study, outlined in a poster at ASHP Midyear 2023, identified 3 key themes associated with the ways in which pharmacists are positioned to advance health equity for patients with chronic diseases.
Assessing Financial Impacts of Pharmacist-Led Interventions in Pediatric Ambulatory Care
December 5th 2023According to a poster abstract presented at the ASHP Midyear Clinical Meeting & Exhibition, specialty pharmacy services were used for a variety of conditions that have been reported in adult populations.
